Giles Brown PhD, MBA, FRSC
Senior VP Chemistry
Giles has over 20 years’ experience working in Biotech and has established a proven track record in delivering small molecule preclinical and clinical candidates across multiple therapeutic areas (incl. CNS, Inflammation, Oncology and Immuno-Oncology). Most recently Giles was Senior Vice President, Medicinal Chemistry at Dunad Therapeutics where he developed the company’s novel tunable mono-valent degrader chemistry platform for drug discovery. Prior to this he was Vice President of Medicinal Chemistry at OMass Therapeutics where he contributed to building the organisation and developing the company’s native mass spectrometry platform for drug discovery.
Formerly in his career, Giles was Head of Medicinal Chemistry at Sosei Heptares and helped develop the StaR® structural biology platform as a new approach to structure-based drug design for GPCRs.
Giles received a BSc in Chemistry and a PhD in Organic Chemistry from the University of Bristol, he followed this with a period of post-doctoral research at the University of Pennsylvania. He also has an MBA from Henley Business School. Giles is a Fellow of the Royal Society of Chemistry and an author of over 70 patents and peer reviewed publications.